Understanding a global epidemic: Why Africans with HIV are more susceptible to TB

July 23, 2013 by Helen Dodson
Understanding a global epidemic: Why Africans with HIV are more susceptible to TB

Yale researchers have identified a common genetic variant that makes people infected with HIV much more susceptible to tuberculosis (TB). The study is published in the online Early Edition of the Proceedings of the National Academy of Sciences.

Tuberculosis is the leading cause of death by infectious disease, causing 1.5 million deaths around the world each year. Its prevalence is rising because of drug resistance and an increasing number of patients who are co-infected with HIV. They represent nearly 30 percent of all TB-related deaths. The convergence of these epidemics is particularly prominent on the African continent, which has the highest rates of TB cases and deaths—80 percent of which occur in people living with HIV. Globally, a higher incidence of tuberculosis is known to occur in Africans and African-Americans than in American or European Caucasians, and has long been suspected.

The Yale-led team found that a low-expressing version of the immune response gene known as macrophage migration inhibitory factor (MIF)—a cell-signaling molecule secreted by the body's —conferred a two-and-a-half two and a half-fold increased risk for severe tuberculosis in a group of patients from Uganda. Low-expressers of MIF are almost twice as common among people of African ancestry as Caucasians.

"This helps to explain the increased incidence of TB in Africa," said senior author Richard Bucala, M.D., professor of rheumatology, pathology, and epidemiology at Yale School of Medicine and Yale School of Public Health.

Furthermore, this variation may be especially important in people co-infected with HIV, who have a compromised immune system. "Therapies to augment MIF action could provide a new tool to combat the global TB epidemic," Bucala said.

Other authors are Rituparna Das of Yale and the University of Pennsylvania; Bae Hoon Kim, Jie Yao, Lin Leng, Rebecca Levy, Charles Murchison, and John MacMicking of Yale; Mi-Sun Koo, Selvakumar Subbian, and Gilla Kaplan of the University of Medicine and Dentistry of New Jersey; Shevin Jacob of the University of Washington; William Burman of the University of Colorado; Christopher Moore of the University of Virginia; and John David of Harvard School of Public Health.

Explore further: Scientists to study the role genes play in treating tuberculosis

Related Stories

Scientists to study the role genes play in treating tuberculosis

October 25, 2012
The University of Liverpool has been awarded funding to determine whether differences in our genes determine how patients respond to drugs used to treat Tuberculosis (TB) in Sub-Saharan Africa.

Still long delays in diagnosing TB and HIV

May 31, 2013
It still takes a long time for TB and HIV patients in Uganda to be properly diagnosed. As a result, many patients are infectious without knowing it themselves. These diagnostic delays, and also adherence to therapy, can be ...

Scientists discover ethnic differences in immune response to TB bacterium

July 4, 2013
The immune response to the bacterium that causes tuberculosis (TB) varies between patients of different ethnic origin, raising important implications for the development of tests to diagnose and monitor treatment for the ...

Tuberculosis in US hits record low

March 21, 2013
Cases of tuberculosis reached an all-time low in the United States last year, but the disease continued to affect minorities at much higher rates than whites, health authorities said Thursday.

Experimental vaccine elicits robust response against both HIV and tuberculosis

May 22, 2012
Clinician researchers in China have developed a vaccine that acts simultaneously against HIV-1 and M. tuberculosis (Mtb). An estimated 14 million people worldwide are coinfected with the two pathogens. The research is published ...

Recommended for you

Study opens new avenue in quest to develop tuberculosis vaccine

November 24, 2017
A team of scientists led by the University of Southampton has taken an important step forward in research efforts that could one day lead to an effective vaccine against the world's deadliest infectious disease.

Four simple tests could help GPs spot pneumonia and reduce unnecessary antibiotics

November 23, 2017
Testing for fever, high pulse rate, crackly breath sounds, and low oxygen levels could be key to helping GPs distinguish pneumonia from less serious infections, according to a large study published in the European Respiratory ...

New approach to tracking how deadly 'superbugs' travel could slow their spread

November 22, 2017
Killer bacteria - ones that have out-evolved our best antibiotics—may not go away anytime soon. But a new approach to tracking their spread could eventually give us a fighting chance to keep their death toll down.

Research points to diagnostic test for top cause of liver transplant in kids

November 22, 2017
Biliary atresia is the most common cause of liver transplants for children in the United States. Now researchers report in Science Translational Medicine finding a strong biomarker candidate that could be used for earlier ...

Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

November 22, 2017
A new study provides insights into the interaction between alcohol consumption and metabolic factors in predicting severe liver disease in the general population. The findings, which are published in Hepatology, indicate ...

Metabolites altered in chronic kidney disease

November 22, 2017
Chronic kidney disease (CKD) affects 1 in 7 people in the United States, according to the U.S. National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK). These individuals have a very high risk of cardiovascular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.